Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aetna Inc.
Next round of biomedical innovation legislation provides opportunity to require insurance reimbursement of investigational drugs and related medical services, as well as new incentives for small biotech companies to offer expanded access programs, stakeholders say.
Recent mergers between PBMs and insurers should address one long-term strategic objective of pharma – the recognition by payors of the value of biopharmaceutical products in relation to other medical costs.
US Action Collaborative plans to align guidelines for acute and chronic pain indications; panelist at public meeting questions whether focus should be on pain management rather than opioids.
The proposal to eliminate rebates in the US raises important follow up questions, including who will be responsible for pharmacy transactions at the point of sale. PBMs say they should stay in that role to assure a smooth transition; independent pharmacies have other ideas.